{"id":23748,"date":"2020-08-06T10:44:39","date_gmt":"2020-08-06T14:44:39","guid":{"rendered":"http:\/\/stateofthenation.co\/?p=23748"},"modified":"2020-08-06T10:44:39","modified_gmt":"2020-08-06T14:44:39","slug":"modernagate-bill-gates-busted-queen-implicated-wellcome-trust-incriminated","status":"publish","type":"post","link":"http:\/\/stateofthenation.co\/?p=23748","title":{"rendered":"MODERNAgate: Bill Gates Busted, Queen Implicated & Wellcome Trust Incriminated"},"content":{"rendered":"

MODERNA\u2019S TOTALLY DISQUALIFYING RED FLAG \u201cSTRATEGIC\u201d RELATIONSHIPS TO THE QUEEN, WELLCOME TRUST, AND BILL GATES<\/h1>\n

Americans for Innovation
\nAim4Truth.org<\/a><\/p>\n

\n

Readers:<\/strong> This is a work in progress. Please check back in another day to see what else we have found out about this INSIDER TRADING<\/strong> group. We will be adding material as it comes in from the mines.<\/p>\n

Mike and Doug explain what this disclosure means in our war with the \u2018Invisible Enemy\u2019.<\/p>\n

\"Insider<\/span><\/p>\n

\n
\n

RAW AUDIO FILE: HTTPS:\/\/AIM4TRUTH.ORG\/WP-CONTENT\/UPLOADS\/2020\/08\/MASSIVE-INSIDER-TRADING-AT-MODERNA-INC.-.MP3<\/a><\/h3>\n
\n

MODERNA INC (MRNA) STOCK FRAUD<\/strong><\/h1>\n

Bill Gates, AztraZeneca (the British Crown, Rothschild), Goldman Sachs, J.P. Morgan (Rothschild), Morgan Stanley. Barclays (Rothschild), Bank of America, Vertex Pharmaceuticals (Rothschild), Merck, DARPA (the U.S. Defense Department!) ALL MUST BE DISQUALIFIED AND DISMISSED FROM INVOLVEMENT WITH CORONAVIRUS treatment recommendations involving Moderna, or Moderna associated INTERLOCKING RELATIONSHIPS that are both monopolistic and seditious.<\/p>\n

Moderna, Inc., CIK# 0001682852. (Filed Dec. 04, 2018)<\/a>. Form S-1\/A Initial Public Offering. SEC Edgar.<\/p>\n

https:\/\/www.fbcoverup.com\/docs\/library\/2018-12-04-Moderna-Inc-MRNA-CIK-0001682852-S-1A-Initial-Public-Offering-SEC-Edgar-Filed-Dec-04-2018.pdf<\/a><\/p>\n

Also,<\/p>\n

https:\/\/www.sec.gov\/Archives\/edgar\/data\/1682852\/000119312518341958\/d611137ds1a.htm<\/a><\/p>\n

\"platform\"<\/span><\/p>\n

(About 100 patents have been issued in the U.S. Moderna does not disclose the numbers in their S-1\/A.)<\/p>\n

\"patent<\/span><\/p>\n

.<\/p>\n

MODERNA (NASDAQ: MRNA) INSIDER TRADING REPORTS (FORM 4)<\/h1>\n

CEO Stephan Bancel<\/strong><\/p>\n

Key officers and directors: Sell, Sell, Sell!<\/h3>\n

https:\/\/www.sec.gov\/cgi-bin\/own-disp?action=getissuer&CIK=0001682852<\/a><\/p>\n

(Note to readers: We will have this chart formatted in a better way shortly.)<\/em><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Owner<\/strong><\/a><\/td>\nFilings<\/strong><\/a><\/td>\nTransaction Date<\/strong><\/a><\/td>\nType of Owner<\/strong><\/a><\/td>\n<\/tr>\n
Bancel Stephane<\/a><\/td>\n0001443340<\/a><\/td>\n2020-07-29<\/td>\ndirector, officer: Chief Executive Officer<\/td>\n<\/tr>\n
Zaks Tal Zvi<\/a><\/td>\n0001690927<\/a><\/td>\n2020-07-27<\/td>\nofficer: Chief Medical Officer<\/td>\n<\/tr>\n
Hoge Stephen<\/a><\/td>\n0001760669<\/a><\/td>\n2020-07-23<\/td>\nofficer: President<\/td>\n<\/tr>\n
NABEL ELIZABETH G<\/a><\/td>\n0001619929<\/a><\/td>\n2020-07-15<\/td>\ndirector<\/td>\n<\/tr>\n
Tallett Elizabeth E<\/a><\/td>\n0001192460<\/a><\/td>\n2020-07-01<\/td>\ndirector<\/td>\n<\/tr>\n
HENDERSON LORI M.<\/a><\/td>\n0001221127<\/a><\/td>\n2020-06-18<\/td>\nofficer: General Counsel and Secretary<\/td>\n<\/tr>\n
Meline David W<\/a><\/td>\n0001444612<\/a><\/td>\n2020-06-08<\/td>\nofficer: Chief Financial Officer<\/td>\n<\/tr>\n
Kim Lorence H.<\/a><\/td>\n0001643746<\/a><\/td>\n2020-06-02<\/td>\nofficer: Chief Financial Officer<\/td>\n<\/tr>\n
AFEYAN NOUBAR<\/a><\/td>\n0001222012<\/a><\/td>\n2020-05-21<\/td>\ndirector, 10 percent owner<\/td>\n<\/tr>\n
Flagship Ventures Fund IV, L.P.<\/a><\/td>\n0001503559<\/a><\/td>\n2020-05-21<\/td>\n10 percent owner<\/td>\n<\/tr>\n
Flagship Ventures Fund IV General Partner LLC<\/a><\/td>\n0001508051<\/a><\/td>\n2020-05-21<\/td>\ndirector, 10 percent owner<\/td>\n<\/tr>\n
Flagship Ventures Fund IV-Rx, L.P.<\/a><\/td>\n0001590973<\/a><\/td>\n2020-05-21<\/td>\n10 percent owner<\/td>\n<\/tr>\n
Andres Juan<\/a><\/td>\n0001760670<\/a><\/td>\n2020-05-13<\/td>\nofficer: See remarks<\/td>\n<\/tr>\n
SAGAN PAUL<\/a><\/td>\n0001035440<\/a><\/td>\n2020-04-29<\/td>\ndirector<\/td>\n<\/tr>\n
LANGER ROBERT<\/a><\/td>\n0001239757<\/a><\/td>\n2020-04-29<\/td>\ndirector<\/td>\n<\/tr>\n
Nader Francois<\/a><\/td>\n0001365343<\/a><\/td>\n2020-04-29<\/td>\ndirector<\/td>\n<\/tr>\n
Horning Sandra<\/a><\/td>\n0001638709<\/a><\/td>\n2020-04-29<\/td>\ndirector<\/td>\n<\/tr>\n
Slaoui Moncef<\/a><\/td>\n0001712369<\/a><\/td>\n2020-04-29<\/td>\ndirector<\/td>\n<\/tr>\n
Berenson Stephen<\/a><\/td>\n0001760671<\/a><\/td>\n2020-04-29<\/td>\ndirector<\/td>\n<\/tr>\n
LEE JENNIFER LING<\/a><\/td>\n0001675118<\/a><\/td>\n2020-03-09<\/td>\nofficer: Chief Accounting Officer<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\"moderna-mrna-stock-chart-accessed-am-aug-04-2020\"<\/span><\/p>\n\n\n\n
Bancel Stephane<\/a><\/td>\n0001443340<\/a><\/td>\n2020-07-29<\/td>\ndirector, officer: Chief Executive Officer<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

https:\/\/www.fbcoverup.com\/docs\/library\/2020-07-29-Moderna-Stephane-Bancel-CEO-Sold-$31M-shares-SEC-FORM-4-Jul-29-2020.pdf<\/a><\/p>\n

\"stephane<\/span><\/p>\n

Sold $30,840,614 in shares in his name assigned to Boston Biotech, LLC; Bancel children; OCJA LLC (personal LLC); personally.<\/p>\n

https:\/\/www.crunchbase.com\/organization\/bb-biotech-ventures<\/a><\/p>\n

A Zurich, Switzerland company. Guernsey (offshore) based). Martin Munchbach, Managing Director. Bellevue Asset Management AG.<\/p>\n

http:\/\/www.bbbiotechventures.com\/en\/bb-biotech-ventures\/<\/a><\/p>\n

Relationships with Sanofi, Roche, Booz Allen, Genencor, Genzyme, Genentech (Rothschild), Novartis, Ciba-Geigy, Glaxo, Seimens, Hoffman-Roche, Harvard,<\/p>\n

. . . . . . .<\/h3>\n

FYI. Ole Stevie boy has been selling his stock out since Nov. 2019.<\/p>\n

NO BUYS. ALL SELLS.<\/h2>\n

https:\/\/www.fbcoverup.com\/docs\/library\/2020-08-03-Stephane-Bancel-CEO-Moderna-Inc-Form-D-Insider-Trading-Report-SEC-accessed-Aug-03-2020.pdf<\/a><\/p>\n

\"bancel<\/span><\/p>\n

https:\/\/yuzuha.substack.com\/p\/interview-with-moderna-ceo-stephane<\/a><\/p>\n

. . . . . . .<\/h3>\n

Moderna\u2019s latest Proxy Statement Form DEF 14A dated Apr. 10, 2020<\/strong><\/p>\n

MASSIVE WELLCOME TRUST CONFLICT OF INTEREST<\/strong><\/h2>\n

Includes numerous conflicting relationships with Goldman Sachs, J.P. Morgan, Wellcome Trust (GlaxoSmithKline \u2013 GSK), Harvard, UPenn, Stanford, Merck, Novartis, Sanofi, McKinsey, London School of Economics (notorious promoter of communist ideology), Medtronic, MIT, Dell, Roche, Hoffman-Roche, VMware,<\/p>\n

Moderna\u2019s CEO Stephane Bancel and Chief Medical Officer Tal Zaks, MD, Phd<\/a> have been big stock sellers for a year. Zaks was director of clinical development and translational medice for GLAXOSMITHKLINE (Wellcome Trust \u2013 co-owner of the Coronavisur Patent along with the Gates Foundation. THIS CONFLICT IS ALONE IS DISQUALIFYING & FRAUDULENT GIVE GLAXO\u2019S RELATIONSHIP WITH THE PIRBRIGHT INSTITUTE (UK). https:\/\/heightzone.com\/dr-tal-zaks\/<\/a><\/p>\n

Israeli Tal Zaks \u2013 Been only selling his Moderna stock (dumping) since Dec. 2019<\/strong><\/p>\n

This guy is evidently dumping his Moderna shares while he is promoting his supposed COVID vaccine.<\/strong><\/p>\n

That is illegal stock manipulation and should land him and his CEO in jail. <\/strong><\/p>\n

C\u2019mon Bill Barr, do your job.<\/strong><\/p>\n

\"stephane
Moderna\u2019s Israeli Chief Medical Officer Tal Zaks<\/strong> has been dumping his stock since December 2019, just one month after CEO Stephane Bancel starting dumping his. Where is the SEC, Bill Barr, the underwriters? The US stock market IPO system is totally rigged for the Pilgrims Society in Britain and America.<\/figcaption><\/figure>\n

https:\/\/www.sec.gov\/Archives\/edgar\/data\/1682852\/000119312520103908\/d915867ddefa14a.htm<\/a><\/p>\n

Moderna, Inc. (Filer)\u00a0<\/strong>CIK<\/strong>:\u00a00001682852 (see all company filings)<\/a><\/strong><\/p>\n

IRS No.:\u00a0813467528<\/strong>\u00a0| State of Incorp.:\u00a0DE<\/strong>\u00a0| Fiscal Year End:\u00a01231<\/strong>
\nType:\u00a0DEFA14A<\/strong>\u00a0| Act:\u00a034<\/strong>\u00a0| File No.:\u00a0001-38753<\/strong><\/a>\u00a0| Film No.:\u00a020787049<\/strong>
\nSIC:\u00a02836<\/a><\/strong>\u00a0Biological Products, (No Diagnostic Substances)
\nOffice of Life Sciences<\/p>\n

MANAGEMENT<\/strong><\/p>\n

Executives, non-executive directors and director nominee<\/strong><\/p>\n

The following table sets forth the name, age and position of each of our executives,\u00a0non-executive\u00a0directors and director nominee as of March\u00a02, 2020.<\/p>\n

https:\/\/www.sec.gov\/Archives\/edgar\/data\/1682852\/000119312520103908\/d915867ddefa14a.htm<\/a><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
MANAGEMENT<\/td>\nSee Resumes:<\/td>\nAt the bottom of this post.<\/td>\n<\/tr>\n
Executives,\u00a0non-executive\u00a0directors and director nominee<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
The following table sets forth the name, age and position of each of our executives,\u00a0non-executive\u00a0directors and director nominee as of March\u00a02, 2020.<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
\n
Name<\/div>\n<\/td>\n
Age<\/td>\nPosition<\/td>\n<\/tr>\n
Executives:<\/strong><\/td>\n<\/td>\n<\/td>\n<\/tr>\n
St\u00e9phane Bancel\u00a0(1)<\/td>\n47<\/td>\nChief Executive Officer and Director<\/td>\n<\/tr>\n
Juan Andres\u00a0(1)<\/td>\n55<\/td>\nChief Technical Operations and Quality Officer<\/td>\n<\/tr>\n
Marcello Damiani<\/td>\n50<\/td>\nChief Digital and Operational Excellence Officer<\/td>\n<\/tr>\n
Tracey Franklin<\/td>\n40<\/td>\nChief Human Resources Officer<\/td>\n<\/tr>\n
Lori Henderson, J.D.\u00a0(1)<\/td>\n58<\/td>\nGeneral Counsel and Corporate Secretary<\/td>\n<\/tr>\n
Stephen Hoge, M.D.\u00a0(1)<\/td>\n44<\/td>\nPresident<\/td>\n<\/tr>\n
Lorence Kim, M.D.\u00a0(1)<\/td>\n45<\/td>\nChief Financial Officer<\/td>\n<\/tr>\n
Tal Zaks, M.D., Ph.D.\u00a0(1)<\/td>\n54<\/td>\nChief Medical Officer<\/td>\n<\/tr>\n
Non-Executive\u00a0Directors:<\/strong><\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Noubar B. Afeyan, Ph.D.\u00a0(4)(5)<\/td>\n57<\/td>\nChairman, Director<\/td>\n<\/tr>\n
Stephen Berenson\u00a0(2)(3)<\/td>\n59<\/td>\nDirector<\/td>\n<\/tr>\n
Robert Langer, Sc.D.\u00a0(4)<\/td>\n71<\/td>\nDirector<\/td>\n<\/tr>\n
Elizabeth Nabel, M.D.\u00a0(4)(5)<\/td>\n68<\/td>\nDirector<\/td>\n<\/tr>\n
Fran\u00e7ois Nader, M.D.(5)<\/td>\n63<\/td>\nDirector<\/td>\n<\/tr>\n
Israel Ruiz(2)(3)<\/td>\n48<\/td>\nDirector<\/td>\n<\/tr>\n
Paul Sagan\u00a0(2)(3)<\/td>\n61<\/td>\nDirector<\/td>\n<\/tr>\n
Moncef Slaoui, Ph.D.(5)<\/td>\n60<\/td>\nDirector<\/td>\n<\/tr>\n
Director Nominee:<\/strong><\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Sandra Horning, M.D.<\/td>\n71<\/td>\nDirector nominee<\/td>\n<\/tr>\n
<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
-1<\/td>\nExecutive officer<\/td>\n<\/td>\n<\/tr>\n
-2<\/td>\nMember of the Audit Committee<\/td>\n<\/td>\n<\/tr>\n
-3<\/td>\nMember of the Compensation and Talent Committee<\/td>\n<\/td>\n<\/tr>\n
-4<\/td>\nMember of the Nominating and Corporate Governance Committee<\/td>\n<\/td>\n<\/tr>\n
-5<\/td>\nMember of the Product Development Committee<\/td>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

See the resumes of the above-mentioned people at the bottom of this post.<\/em> These relationships alone should fundamentally disqualify Moderna or any of its INTERLOCKING<\/strong> relationships from any involvement in Coronavirus.<\/p>\n

https:\/\/www.sec.gov\/Archives\/edgar\/data\/1682852\/000119312518341958\/d611137ds1a.htm<\/a><\/p>\n

\"moderna<\/span><\/p>\n

.<\/p>\n

\"moderna<\/span><\/p>\n

\u201cSince we nominated our first program in late 2014, we and our strategic collaborators have advanced in parallel a diverse development pipeline of 21 programs, of which 10 have entered clinical studies and another 3 have open INDs. Our therapeutic and vaccine development programs span infectious diseases, oncology, cardiovascular diseases, and rare genetic diseases. We have assembled an exceptional team of approximately 700 employees and have established strategic alliances with leading biopharmaceutical companies, including AstraZeneca, Merck\u00a0& Co., and Vertex Pharmaceuticals, as well as government-sponsored and private organizations focused on global health initiatives, including Biomedical Advanced Research and Development Authority, or BARDA, Defense Advanced Research Projects Agency, or DARPA, and the Bill\u00a0& Melinda Gates Foundation. As of September\u00a030, 2018, we have raised over $2.6\u00a0billion in total funding from our strategic collaborators and investors, and have cash, cash equivalents, and investments of $1.2\u00a0billion. As we unlock the inherent advantages of mRNA, we aim to address as many diseases and impact as many patients as our technology, talent, and capital permit.\u201d<\/p>\n

\"moderna<\/span><\/p>\n

\"mRNA\"<\/span><\/p>\n

AZ = AstraZeneca (ICI, controlled by the Queen\u2019s Golden Share)<\/h3>\n

\"mrna<\/span><\/p>\n

https:\/\/www.sec.gov\/Archives\/edgar\/data\/1443340\/000112760220022435\/xslF345X03\/form4.xml<\/a><\/p>\n

MODERNA CEO STEPHANE BANCEL IS THE DICTIONARY DEFINITION OF AN INSIDE CORPORATE TRADER<\/h2>\n

\"non<\/span><\/p>\n

https:\/\/www.sec.gov\/Archives\/edgar\/data\/1443340\/000112760220022138\/xslF345X03\/form4.xml<\/a><\/p>\n

\"non<\/span><\/p>\n

https:\/\/www.sec.gov\/Archives\/edgar\/data\/1443340\/000112760220022102\/xslF345X03\/form4.xml<\/a><\/p>\n

\"non<\/span><\/p>\n

https:\/\/www.sec.gov\/Archives\/edgar\/data\/1443340\/000112760220022102\/xslF345X03\/form4.xml<\/a><\/p>\n

\"non<\/span><\/p>\n

https:\/\/www.sec.gov\/Archives\/edgar\/data\/1443340\/000112760220021763\/xslF345X03\/form4.xml<\/a><\/p>\n

\"non<\/span><\/p>\n

https:\/\/www.sec.gov\/Archives\/edgar\/data\/1443340\/000112760220021495\/xslF345X03\/form4.xml<\/a><\/p>\n

\"non<\/span><\/p>\n

https:\/\/www.sec.gov\/Archives\/edgar\/data\/1443340\/000112760220021332\/xslF345X03\/form4.xml<\/a><\/p>\n

\"non<\/span><\/p>\n

https:\/\/www.sec.gov\/Archives\/edgar\/data\/1443340\/000089924320018777\/xslF345X03\/doc4.xml<\/a><\/p>\n

\"non<\/span><\/p>\n

https:\/\/www.sec.gov\/Archives\/edgar\/data\/1443340\/000112760220020892\/xslF345X03\/form4.xml<\/a><\/p>\n

\"non<\/span><\/p>\n

https:\/\/www.sec.gov\/Archives\/edgar\/data\/1443340\/000110465920079182\/xslF345X03\/a4.xml<\/a><\/p>\n

\"non<\/span><\/p>\n

https:\/\/www.sec.gov\/Archives\/edgar\/data\/1443340\/000112760220020206\/xslF345X03\/form4.xml<\/a><\/p>\n

\"non<\/span><\/p>\n

https:\/\/www.sec.gov\/Archives\/edgar\/data\/1443340\/000112760220019726\/xslF345X03\/form4.xml<\/a><\/p>\n

\"non<\/span><\/p>\n

https:\/\/www.sec.gov\/Archives\/edgar\/data\/1443340\/000112760220018531\/xslF345X03\/form4.xml<\/a><\/p>\n

\"non<\/span><\/p>\n

The above screen captures are but a few of 120 SELLS from late 2019 to current<\/p>\n

See full list of Stephane Bancel Form 4 insider trading reports<\/p>\n

https:\/\/www.sec.gov\/cgi-bin\/browse-edgar?action=getcompany&CIK=0001443340<\/a><\/p>\n

Here\u2019s a full list of the Moderna Insiders<\/p>\n

https:\/\/www.sec.gov\/cgi-bin\/own-disp?action=getissuer&CIK=0001682852<\/a><\/p>\n

\"moderna<\/span><\/p>\n

\"moderna<\/span><\/p>\n

See actual chart entries with hot links above<\/p>\n

\"moderna<\/span><\/p>\n\n\n\n
Bancel Stephane<\/a><\/td>\n0001443340<\/a><\/td>\n2020-07-29<\/td>\ndirector, officer: Chief Executive Officer<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

https:\/\/www.fbcoverup.com\/docs\/library\/2020-07-29-Moderna-Stephane-Bancel-CEO-Sold-$31M-shares-SEC-FORM-4-Jul-29-2020.pdf<\/a><\/p>\n

http:\/\/www.bbbiotechventures.com\/en\/bb-biotech-ventures\/<\/a><\/p>\n

\"bb<\/span><\/p>\n

Relationships with Sanofi, Roche, Booz Allen, Genencor, Genzyme, Genentech (Rothschild), Novartis, Ciba-Geigy, Glaxo, Siemens, Hoffman-Roche, Harvard,<\/p>\n

.<\/p>\n

Executives<\/em><\/strong><\/p>\n

St\u00e9phane Bancel<\/em><\/strong>\u00a0has served as our Chief Executive Officer since October 2011 and a member of our board of directors since March 2011.\u00a0Before joining the Company, Mr.\u00a0Bancel served for five years as Chief Executive Officer of the French diagnostics company bioM\u00e9rieux SA (Euronext: BIM). From July 2000 to March 2006, he served in various roles at Eli Lilly and Company (NYSE: LLY), including as Managing Director, Belgium, and as Executive Director, Global Manufacturing Strategy and Supply Chain. Prior to Eli Lilly and Company, Mr.\u00a0Bancel served as Asia-Pacific Sales and Marketing Director for bioM\u00e9rieux. Mr.\u00a0Bancel currently serves on the board of directors of Qiagen N.V. (NYSE: QGEN) and previously served on the boards of directors of BG Medicine, Inc. (OTCMKTS: BGMD) and Syros Pharmaceuticals, Inc. (Nasdaq: SYRS).\u00a0He is currently a Venture Partner at Flagship Pioneering and a trustee of the Museum of Science in Boston. Mr.\u00a0Bancel holds a Master of Engineering degree from \u00c9cole Centrale Paris (ECP), a Master of Science in chemical engineering from the University of Minnesota, and an M.B.A. from Harvard Business School. We believe that Mr.\u00a0Bancel is qualified to serve on our board of directors because of his extensive leadership experience in the healthcare industry and experience as a director of public and private companies.<\/p>\n

Juan Andres<\/em><\/strong>\u00a0joined the Company in August 2017, and has served as our Chief Technical Operations and Quality Officer since August 2018. Before joining the Company, Mr.\u00a0Andres worked at Novartis AG (NYSE: NVS) from<\/p>\n

10<\/h5>\n
TABLE OF CONTENTS<\/a><\/h5>\n

2005 to 2017, in various roles of increasing responsibility including serving as Global Head, Technical Operations (Manufacturing and Supply Chain), Global Head of Quality, and Global Head of Technical Research and Development. From 1987 to 1996, Mr.\u00a0Andres served in various\u00a0manufacturing, production, and quality roles\u00a0at Eli Lilly and Company (NYSE: LLY), including as Vice President, Pharmaceutical Manufacturing. Mr.\u00a0Andes has served as a member of the board of directors of Evelo Biosciences, Inc. (Nasdaq: EVLO) since December 2019, and of Avantor, Inc. (NYSE: AVTR), since September 2019. Mr.\u00a0Andres obtained a degree in pharmacy at the Universidad de Alcal\u00e1 in Spain.<\/p>\n

Marcello Damiani<\/em><\/strong>\u00a0joined the Company in May 2015, and has served as our Chief Digital and Operational Excellence Officer since September 2018. From 2009 to 2015, Mr.\u00a0Damiani held senior roles at bioM\u00e9rieux (Euronext: BIM), including Senior Vice President and Group Chief Information Officer. Mr.\u00a0Damiani holds an M.S. degree in Information Systems Architecture from the University of Toulouse, France and completed an international Executive M.B.A. program through TRIUM, an alliance of the London School of Economics, the NYU Stern Business School, and the HEC Paris School of Management, France.<\/p>\n

Tracey Franklin<\/em><\/strong>\u00a0has served as our Chief Human Resources Officer since October 2019. From 2004 to October 2019, Ms.\u00a0Franklin held positions of increasing responsibility at Merck\u00a0& Co., Inc., including most recently Vice President, HR Chief Talent and Strategy Officer. Ms.\u00a0Franklin holds a B.A. in communication arts and sciences from Pennsylvania State University and a Masters in industrial and organizational psychology from Fairleigh Dickinson University.<\/p>\n

Lori Henderson, J.D.<\/em><\/strong>, has served as our General Counsel and Corporate Secretary since April 2018. From 2011 to 2018, Ms.\u00a0Henderson served at Albany Molecular Research Inc. (Nasdaq: AMRI) first as Vice President, General Counsel and Corporate Secretary until 2014 and then as Senior Vice President, General Counsel and Head of Business Development. Prior to her time at AMRI, Ms.\u00a0Henderson worked as a corporate attorney at Goodwin Procter LLP and as a General Counsel at other corporations. She received her J.D. from the George Washington University Law School and her B.A. in Business and Economics from Gordon College.<\/p>\n

Stephen Hoge, M.D.<\/em><\/strong>, joined the Company in January 2013 and has served as our President since February 2015. From 2010 to 2012, Dr.\u00a0Hoge was a Partner at McKinsey\u00a0& Company and a leader in the firm\u2019s healthcare practice. From 2005 to 2010, he served in roles of increasing responsibility at McKinsey\u00a0& Company.\u00a0From 2004 to 2005, Dr.\u00a0Hoge was a resident physician at New York University\/Bellevue Hospital. Dr.\u00a0Hoge has served on the board of directors of Axcella Health, Inc. (Nasdaq: AXLA). He received an M.D. from the University of California, San Francisco and a B.A. in neuroscience from Amherst College.<\/p>\n

Lorence Kim, M.D.<\/em><\/strong>, has served as our Chief Financial Officer since April 2014. From July 2000 to April 2014, Dr.\u00a0Kim held a number of positions at Goldman, Sachs\u00a0& Co., most recently as a Managing Director and\u00a0co-head\u00a0of biotechnology investment banking. Dr.\u00a0Kim has served on the board of directors of Seres Therapeutics, Inc. (Nasdaq: MCRB) since 2014. He received an A.B. in Biochemical Sciences from Harvard University, an M.B.A. in Healthcare Management from the Wharton School of the University of Pennsylvania, and an M.D. from the University of Pennsylvania School of Medicine.<\/p>\n

Tal Zaks, M.D., Ph.D.<\/em><\/strong>, has served as our Chief Medical Officer since March 2015. Prior to joining the Company, Dr.\u00a0Zaks served in senior development positions at Sanofi (NYSE: SNY) from 2010 to 2015, including Senior Vice President and Head of Global Oncology. From July 2008 to May 2010, he served as Vice President of Clinical Research, Oncology at Cephalon. Prior to this, Dr.\u00a0Zaks spent four years at GlaxoSmithKline (NYSE: GSK) as Director, Clinical Development and Translational Medicine and three years at the National Cancer Institute as a Postdoctoral Fellow. He is currently an Associate Professor of Medicine at the University of Pennsylvania and serves on the board of directors of Adaptimmune Therapeutics plc (Nasdaq: ADAP). Dr.\u00a0Zaks received his M.D. and Ph.D. from the Ben Gurion University in Israel and conducted post-doctoral research at the U.S. National Institutes of Health. He completed his clinical training in internal medicine at Temple University Hospital followed by a fellowship in medical oncology at the University of Pennsylvania.<\/p>\n

11<\/h5>\n
TABLE OF CONTENTS<\/a><\/h5>\n

Non-executive\u00a0directors<\/em><\/strong><\/p>\n

Noubar B. Afeyan, Ph.D.<\/em><\/strong>, is a\u00a0co-founder\u00a0and has served on our board of directors since incorporation, and has served as a chairman of our board of directors since February 2012. In 1999, Dr.\u00a0Afeyan founded Flagship Pioneering and serves as its Senior Managing Partner and Chief Executive Officer. Since April 2013, Dr.\u00a0Afeyan has served on the board of directors of Rubius Therapeutics, Inc. (Nasdaq: RUBY) and since October 2010, on the board of Seres Therapeutics, Inc. (Nasdaq: MCRB). He currently serves on the boards of numerous privately held companies, and has previously served on the boards of numerous privately and publicly held companies, including Evelo Biosciences, Inc. (Nasdaq: EVLO), Kaleido Biosciences, Inc. (Nasdaq: KLDO) and BG Medicine, Inc (OTCMKTS: BGMD). He received a Ph.D. in biochemical engineering from the Massachusetts Institute of Technology (\u201cMIT\u201d) and a B.S. in chemical engineering from McGill University. Dr.\u00a0Afeyan is currently a visiting lecturer of business administration at Harvard Business School and was previously a senior lecturer at MIT\u2019s Sloan School of Management where he taught courses on technology-entrepreneurship, innovation, and leadership. We believe that Dr.\u00a0Afeyan\u2019s significant experience\u00a0co-founding,\u00a0leading, and investing in numerous biotechnology companies make him qualified to serve on our board of directors.<\/p>\n

Stephen Berenson<\/em><\/strong>\u00a0has served as a member of our board of directors since October 2017. Mr.\u00a0Berenson is a Managing Partner at Flagship Pioneering. Prior to that, Mr.\u00a0Berenson spent 33 years as an investment banker at J.P. Morgan. During his last twelve years at J.P. Morgan, Mr.\u00a0Berenson was Vice Chairman of Investment Banking and focused on providing high-touch strategic advice and complex transaction execution to leading companies across all industries globally. He was\u00a0co-founder\u00a0of J.P. Morgan\u2019s Global Strategic Advisory Council and\u00a0co-founder\u00a0of the firm\u2019s Board Initiative. Mr.\u00a0Berenson also serves as Chairman of the board of directors of Seres Therapeutics, Inc. (Nasdaq: MCRB) and on the board of directors of CiBO Technologies, Inc. Mr.\u00a0Berenson received an S.B. in mathematics from MIT. We believe that Mr.\u00a0Berenson is qualified to serve on our board of directors because of his experience in the banking and investment industries.<\/p>\n

Robert Langer, Sc.D.<\/em><\/strong>, has served as a member of our board of directors since December 2010. Dr.\u00a0Langer has been an Institute Professor at MIT since 2005, and prior to that was a Professor at MIT beginning in 1977. Dr.\u00a0Langer currently serves on the board of directors of Rubius Therapeutics, Inc. (Nasdaq: RUBY), Kala Pharmaceuticals, Inc. (Nasdaq: KALA), and the UK public company Puretech Health plc (LON: PRTC), and previously served on the board of directors of Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), Wyeth (NYSE: WYE), Fibrocell Science, Inc. (Nasdaq: FCSC) and Millipore Corporation (acquired by Merck KGaA in 2010). Dr.\u00a0Langer also served as a member of the Science Board to the U.S. Food and Drug Administration from 1995 to 2002, including his service as chairman from 1999 to 2002. Dr.\u00a0Langer received his B.S. from Cornell University and his Sc.D. from MIT, both in Chemical Engineering. We believe that Dr.\u00a0Langer is qualified to serve on our board of directors because of his pioneering academic work, extensive medical and scientific knowledge and experience, and his previous service on public company boards of directors.<\/p>\n

Elizabeth Nabel, M.D<\/em><\/strong>.<\/em><\/strong>, has served as a member of our board of directors since December 2015. Dr.\u00a0Nabel has served as President of Harvard University-affiliated Brigham Health, which includes Brigham and Women\u2019s Hospital, Brigham and Women\u2019s Faulkner Hospital, and the Brigham and Women\u2019s Physician Organization, since 2010. Dr.\u00a0Nabel has also been a Professor of Medicine at Harvard Medical School since 2010. Prior to that, Dr.\u00a0Nabel held a variety of roles, including Director, at the National Heart, Lung and Blood Institute at the National Institutes of Health, a federal agency funding research, training and education programs to promote the prevention and treatment of heart, lung and blood diseases, from 1999 to 2009. She is an elected member of the National Academy of Medicine of the National Academy of Sciences. Dr.\u00a0Nabel currently serves on the board of directors of Medtronic plc (NYSE: MDT) and as a trustee of Tekla Capital Management LLC. We believe that Dr.\u00a0Nabel is qualified to serve on our board of directors because of her extensive experience in the health care field, including senior positions with a number of research universities and organizations.<\/p>\n

Fran\u00e7ois Nader, M.<\/em><\/strong>D.<\/em><\/strong>, has served as a member of our board of directors since December 2019. Dr.\u00a0Nader currently serves as Chairman of the board of directors of Acceleron Pharma Inc. (Nasdaq: XLRN), Prevail<\/p>\n

12<\/h5>\n
TABLE OF CONTENTS<\/a><\/h5>\n

Therapeutics Inc. (Nasdaq: PRVL) and Talaris Therapeutics, Inc. He also serves on the board of directors of Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) and as an advisor for SVB Leerink. Dr.\u00a0Nader\u00a0is the past Chairman of BioNJ, New Jersey\u2019s biotechnology trade organization, and previously served on the board of the Biotechnology Industry Organization (BIO), NPS Pharmaceuticals (Nasdaq: NPSP), Advanced Accelerator Applications S.A. (Nasdaq: AAAP), Baxalta Inc. (NYSE: BXLT), Clementia Pharmaceuticals Inc. (Nasdaq: CMTA), Trevena Inc. (Nasdaq: TRVN) and Noven Pharmaceuticals Inc. (Nasdaq: NOVN). Dr.\u00a0Nader\u00a0earned his French doctorate in medicine from St. Joseph University in Lebanon and a physician executive M.B.A. from the University of Tennessee. We believe that Dr.\u00a0Nader is qualified to serve on our board of directors because of his experience in integrated healthcare markets and medical and regulatory affairs and his service on numerous boards of directors.<\/p>\n

Israel Ruiz<\/em><\/strong>\u00a0has served as a member of our board of directors since February 2017. Mr.\u00a0Ruiz has been the Executive Vice President and Treasurer at MIT since 2011. In this role, Mr.\u00a0Ruiz oversees all principal administrative and financial functions of MIT. Prior to his current role, Mr.\u00a0Ruiz served as the Vice President for Finance for MIT from 2007 to 2011 and as a principal for MIT\u2019s Office of Budget and Financial Planning from 2001 to 2007. He currently serves on the board of directors of FM Global and previously served on the board of directors of Fortive Corporation (NYSE: FTV). Mr.\u00a0Ruiz received a degree in industrial and mechanical engineering from the Polytechnic University of Catalonia and a master\u2019s degree from the MIT Sloan School of Management. We believe that Mr.\u00a0Ruiz is qualified to serve on our board of directors because of his deep financial and accounting experience as the chief financial officer of MIT.<\/p>\n

Paul Sagan<\/em><\/strong>\u00a0has served as a member of our board of directors since June 2018. Mr.\u00a0Sagan has been a Managing Director at General Catalyst Partners, a venture capital firm, since January 2018, and previously served as an Executive In Residence (XIR) since January 2014. From April 2005 to January 2013, Mr.\u00a0Sagan served as Chief Executive Officer at Akamai Technologies, Inc. (Nasdaq: AKAM) and was President from May 1999 to September 2010 and from October 2011 to January 2013. He was also a director of Akamai Technologies until 2019. Mr.\u00a0Sagan currently serves on the board of directors of VMware, Inc. (NYSE: VMW) and was a director of EMC from December 2007 until the acquisition by Dell, Inc. in September 2016. Mr.\u00a0Sagan received his B.S. from the Medill School of Journalism at Northwestern University. We believe that Mr.\u00a0Sagan is qualified to serve on our board of directors because of his experience and leadership both in the technology and venture capital fields.<\/p>\n

Moncef Slaoui, Ph.D.<\/em><\/strong>, has served as a member of our board of directors since July 2017. Dr.\u00a0Slaoui joined GlaxoSmithKline Plc (NYSE: GSK) (\u201cGSK\u201d) in 1988, where he engineered the development of a robust vaccines pipeline. He then led worldwide business development for pharmaceutical products before his appointment to lead research and development in 2006. He assumed overall responsibility for GSK\u2019s Oncology Business in 2010, for GSK Vaccines in 2011, and for all Global Franchises in 2012. Dr.\u00a0Slaoui is Chairman of the board of directors of Galvani Bioelectronics, a company launched in November 2016 that GSK jointly owns with Verily Life Sciences. Dr.\u00a0Slaoui has advised the U.S. President\u2019s Council of Advisors on Science and Technology, was a member of the Board of the Agency for Science, Technology,\u00a0& Research until January 2011, the PhRMA Foundation Board from 2008 to 2016, and the Advisory Committee to the Director of the National Institutes of Health from 2011 to 2016. Dr.\u00a0Slaoui previously served on the board of directors of Intellia Therapeutics Inc. (Nasdaq: NTLA). Dr.\u00a0Slaoui is also a former Professor of Immunology at the University of Mons, Belgium. Dr.\u00a0Slaoui received a Ph.D. in Molecular Biology and Immunology from Universit\u00e9 Libre de Bruxelles. We believe that Dr.\u00a0Slaoui is qualified to serve on our board of directors because of his vast experience in the pharmaceutical industry and various leadership positions.<\/p>\n

Director nominee<\/em><\/strong><\/p>\n

Sandra Horning, M.D<\/em><\/strong>.,\u00a0<\/em><\/strong>is nominated to serve as a Class\u00a0II director on our board. Dr.\u00a0Horning was the Chief Medical Officer and Global Head of Product Development of Roche, Inc., from 2009 until her retirement in 2019. Prior to Roche, Dr.\u00a0Horning spent 25 years as a practicing oncologist, investigator and tenured professor at the Stanford University School of Medicine, where she remains a professor of medicine emerita. From 2005 to<\/p>\n

13<\/h5>\n
TABLE OF CONTENTS<\/a><\/h5>\n

2006, she served as President of the American Society of Clinical Oncology. From 2015 to 2018, Dr.\u00a0Horning served on the Foundation Medicine Board of Directors. She currently serves as an advisor to EQRx, Inc. Dr.\u00a0Horning received her M.D. from the University of Iowa School of Medicine and completed her post-graduate fellowship in Oncology and Cancer Biology at Stanford University. We believe that Dr.\u00a0Horning is qualified to serve on our board of directors because of her significant experience in the field of oncology and her product development leadership experience.<\/p>\n

. . . . . . .<\/h3>\n

This financial disclosure is from Moderna\u2019s Initial Public Offering (S-1) disclosure filed on Nov. 09, 2018<\/a>.<\/strong><\/p>\n

It shows the interlocking and seditious relationships that disqualify ALL of these actors in the current Coronavirus Scam-demic\u2026 Gates Foundation, DARPA<\/strong>, BARDA, Merck, AstraZeneca (ICI, British government, Queen\u2019s Golden Share)<\/strong> and Moderna\u2019s Israeli chief medical officer Tal Zaks who was a clinical director at GlaxoSmithKline (Wellcome Trust<\/strong>, agent of the Pilgrims Society<\/strong> and the Queen\u2019s Privy Council<\/strong>)<\/p>\n

https:\/\/www.sec.gov\/Archives\/edgar\/data\/1682852\/000119312518323562\/d577473ds1.htm<\/a><\/p>\n

WHERE IS THE DEPARTMENT OF JUSTICE, SPECIFICALLY BILL BARR, ON BUSTING UP THIS INSIDER TRADING GROUP THAT IS TRYING TO EXTERMINATE HUMANITY, WHILE PROFITING A FEW BUCKS?<\/h1>\n

\"bill<\/span><\/p>\n

\n

Postscripts:<\/strong><\/p>\n

Douglas,<\/p>\n

You were so right. Moderna\u2019s intitial public offering documents disloses MONCEF SLAOUI, PHD. as a director. \u00a0He also shows your NIH suspicions true<\/p>\n

https:\/\/www.fbcoverup.com\/docs\/library\/2018-12-04-Moderna-Inc-MRNA-CIK-0001682852-S-1A-Initial-Public-Offering-SEC-Edgar-Filed-Dec-04-2018.pdf#page=307<\/a><\/p>\n

Moncef had been with GlaxoSmithKline (Wellcome Fund)<\/strong> since 1988. He then led worldwide business development then led Glaxo\/Wellcome\u2019s R&D<\/strong> in 2006. He then led the Oncology Business from 2010.<\/p>\n

GSK\/Wellcome Fund jointly own Moncef\u2019s company Galvani Bioelectronics<\/strong>, launched in 2016, with Verily Life Sciences.<\/p>\n

Verily Life Sciences<\/strong> is the new name of what was Google Life Sciences<\/strong>(renamed in 2015). https:\/\/en.wikipedia.org\/wiki\/Verily<\/a><\/p>\n

Enter warmonger Eric Schmidt directly into the Board of Moderna through the back door.<\/p>\n

Moncef Slaoui, Ph.D<\/strong>., has served as a member of our board of directors since July 2017. Dr. Slaoui joined GlaxoSmithKline Plc<\/strong> (NYSE: GSK) (\u201cGSK\u201d) in 1988, where he engineered the development of a robust vaccines pipeline. He then led worldwide business development for pharmaceutical products before his appointment to lead research and development in 2006. He assumed overall responsibility for GSK\u2019s Oncology Business in 2010, for GSK Vaccines in 2011, and for all Global Franchises in 2012. Dr. Slaoui is Chairman of the board of directors of Galvani Bioelectronics<\/strong>, a company launched in November 2016 that GSK jointly owns with Verily Life Sciences<\/strong>. Dr. Slaoui has advised the U.S. President\u2019s Council of Advisors on Science and Technology<\/strong>, was a member of the Board of the Agency for Science, Technology, & Research until January 2011, the PhRMA Foundation Board<\/strong> from 2008 to 2016, and the Advisory Committee to the Director of the National Institutes of Health<\/strong> from 2011 to 2016. Dr. Slaoui previously served on the board of directors of Intellia Therapeutics Inc. (Nasdaq: NTLA)<\/strong>. Dr. Slaoui is also a former Professor of Immunology at the University of Mons, Belgium. Dr. Slaoui received a Ph.D. in Molecular Biology and Immunology from Universit\u00e9 Libre de Bruxelles. We believe that Dr. Slaoui is qualified to serve on our board of directors because of his vast experience in the pharmaceutical industry and various leadership positions.<\/p>\n

MM<\/p>\n

___
\nhttps:\/\/aim4truth.org\/2020\/08\/04\/modernas-totally-disqualifying-red-flag-strategic-relationships-to-the-queen-wellcome-trust-and-bill-gates\/<\/a><\/p>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

MODERNA\u2019S TOTALLY DISQUALIFYING RED FLAG \u201cSTRATEGIC\u201d RELATIONSHIPS TO THE QUEEN, WELLCOME TRUST, AND BILL GATES<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-23748","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"http:\/\/stateofthenation.co\/index.php?rest_route=\/wp\/v2\/posts\/23748","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/stateofthenation.co\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/stateofthenation.co\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/stateofthenation.co\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/stateofthenation.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=23748"}],"version-history":[{"count":0,"href":"http:\/\/stateofthenation.co\/index.php?rest_route=\/wp\/v2\/posts\/23748\/revisions"}],"wp:attachment":[{"href":"http:\/\/stateofthenation.co\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=23748"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/stateofthenation.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=23748"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/stateofthenation.co\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=23748"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}